By Mill Chart
Last update: Sep 6, 2024
Our stock screening tool has pinpointed EXELIXIS INC (NASDAQ:EXEL) as an undervalued stock. NASDAQ:EXEL maintains a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.
ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:EXEL scores a 8 out of 10:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:EXEL scores a 8 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:EXEL has achieved a 8 out of 10:
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:EXEL, the assigned 6 reflects its growth potential:
More Decent Value stocks can be found in our Decent Value screener.
Our latest full fundamental report of EXEL contains the most current fundamental analsysis.
This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
43.04
+0.44 (+1.03%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.